Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Ascendis Pharma A (ASND) over the last 9 years, with Q3 2025 value amounting to -$1.3 million.

  • Ascendis Pharma A's Non-Current Deffered Revenue fell 11095.4% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 11095.4%. This contributed to the annual value of $5.4 million for FY2024, which is 1545.25% down from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Non-Current Deffered Revenue is -$1.3 million, which was down 11095.4% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Non-Current Deffered Revenue ranged from a high of $14.5 million in Q4 2022 and a low of -$4.3 million during Q1 2025
  • Over the past 5 years, Ascendis Pharma A's median Non-Current Deffered Revenue value was $3.3 million (recorded in 2022), while the average stood at $3.1 million.
  • Per our database at Business Quant, Ascendis Pharma A's Non-Current Deffered Revenue skyrocketed by 3114024.28% in 2022 and then tumbled by 33234.38% in 2025.
  • Ascendis Pharma A's Non-Current Deffered Revenue (Quarter) stood at $3.4 million in 2021, then skyrocketed by 327.66% to $14.5 million in 2022, then tumbled by 55.86% to $6.4 million in 2023, then dropped by 16.53% to $5.3 million in 2024, then crashed by 123.72% to -$1.3 million in 2025.
  • Its Non-Current Deffered Revenue was -$1.3 million in Q3 2025, compared to -$3.9 million in Q2 2025 and -$4.3 million in Q1 2025.